IVIG for painful nerve damage
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests if IVIG (intravenous immunoglobulin, a treatment that helps the immune system) can reduce pain in people with small fiber nerve damage or sensory neuronopathy. You may qualify if you have had moderate to severe nerve pain for at least 4 weeks and other conditions have been ruled out.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nerve pain that feels like burning, pins and needles, or unusual sensitivity, lasting at least 4 weeks with a pain level of 5 or higher on a 0-10 scale.
- You have been diagnosed with small fiber neuropathy or sensory neuronopathy through specific tests (like a skin biopsy or nerve test).
- You are not taking any new pain medications in the month before the study starts.
- You do not have diabetes, heart problems, kidney issues, or a history of blood clots.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.
This study tests a multi-sensory (multiple-sense) stimulation approach to see if it can help people with nerve-related pain in the legs/feet. You must be able to safely take part in MRI-related sessions and answer questions about pain and health history.
This trial tests whether a combination of three immune-suppressing drugs (IVIg, cyclophosphamide, and methylprednisolone) given early can improve balance and sensation in people with a rare nerve condition caused by anti-Hu antibodies. The goal is to stop or slow the nerve damage before it gets worse.
This trial tests intravenous immunoglobulin (IVIG), a donated antibody treatment, for people whose gastrointestinal (GI) “motor” symptoms are not improving with standard care and may be auto-immune related. If you’re eligible, IVIG could help calm the immune system and improve gut movement symptoms.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This study tests a new gel (VMD-3866) applied to the skin to treat moderate nerve pain, numbness, or tingling caused by previous chemotherapy. It aims to see if the gel can safely reduce pain for people whose symptoms have been stable for at least 8 weeks.
Hear when a new Sensory Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.